DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW"), a leader in the science, ...
Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at $7.2 billion. Under the terms of the deal, Jazz Pharma will pay $200 per ...
– TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3 – “This is an exciting moment for patients, and their families, ...
GW Pharmaceuticals is looking to blaze new trails in cannabinoid prescription meds, this time in multiple sclerosis. The company has launched a phase 3 trial of nabiximols, known as Sativex outside ...
GW Pharmaceuticals plc GWPH released Monday preliminary unaudited financial results. Net sales for the company's fourth-quarter are expected to be around $148 million. For the full year, GW ...
Disclaimer: The views expressed in this article solely belong to the author and do not necessarily represent those of The Fresh Toast. In 2005, GW hired a vociferous medical marijuana opponent to help ...
Before the drop in price, things were looking great for GW Pharmaceuticals. On Aug. 6, the U.K.-based company released its second-quarter results for the period ended June 30, in which sales of $121.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results